BioSpace News Archive

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity.

Roivant Sciences (Nasdaq: ROIV) today announced positive results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody.

Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) and Tourmaline Bio, Inc. (“Tourmaline”), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced that the companies have entered into a definitive agreement under which Tourmaline will combine with Talaris in an all-stock transaction (the “Merger”).

XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assets.

Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center, located in the Innovation District in Columbus, Ohio.

Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D).

Volta Medical today announced initiation of Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion (RESTART), an interventional clinical trial to be conducted at 16 US and 5 EU sites, evaluating the use of Volta’s AI ablation solution in recurrent-AF patients who failed previous ablations and are now undergoing Volta-supported ablation.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a Commercial Day presentation to provide an overview of its commercial strategy for recently launched LUMRYZ on Thursday, June 29, 2023 beginning at 8:00 a.m. ET.

Vaxxinity, Inc. today announced positive results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson’s disease (PD), demonstrating UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the primary objectives of the trial.

IGM Biosciences, Inc. announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and 7,312,500 shares of its non-voting common stock, in each case at a price to the public of $8.00 per share.